Diagnosis & Disease Information

High-risk cytogenetics and extramedullary disease may be associated with worse survival outcomes of CAR T-cell therapy in relapsed or refractory multiple myeloma, a meta-analysis suggests.

What are some of the most important factors affecting outcomes in patients with multiple myeloma?

Researchers sought to determine whether conversion of MRD status during maintenance would affect risk of disease progression in patients with MM.

Researchers sought to determine whether elotuzumab with pomalidomide and dexamethasone would improve survival in relapsed/refractory multiple myeloma.

Researchers sought to confirm the safety and efficacy of idecabtagene vicleucel in a real-world population of patients with relapsed/refractory multiple myeloma.